Abstract: Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has therefore been regarded as a promising therapeutic strategy in glioblastoma for decades. However, although various pharmacological inhibitors and anti-EGFR antibodies are available, the antiglioma activity of these agents has been largely limited to preclinical models, whereas their administration to glioblastoma patients was characterized by lack of clinical benefit. Comprehensive efforts have been made within the last years to understand the underlying mechanisms that confer resistance to EGFR inhibition in glioma cells. The absence of well-known mutations that predict response to EGFR tyrosine kinase inhibitors (TKIs) in gliomas as well as the presence of redundant and alternative compensatory pathways are among the most important escape mechanisms that prevent potent antiglioma effects of EGFR-targeting drugs. Accordingly, an increasing number of in vitro and in vivo studies are aimed at overcoming this resistance by combinatorial approaches using anti-EGFR treatment together with one or more additional drugs. Novel insights into the molecular mechanisms mediating resistance to anti-EGFR treatment and promising combinatorial approaches may help to better define a future role for EGFR inhibition in the treatment of glioblastoma. 
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General mechanisms of resistance to EGFR-targeted therapies
The escape of glioma cells from EGFR-targeted therapy is caused by several characteristics of these cells and particularly by the existence of multiple overlapping and alternative compensatory signalling pathways which allow for a loss of EGFR function without detrimental effects on the cells 12, 13 . One common finding in glioma cells, that is, loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) has been identified as a resistance factor to drugs directed against EGFR. PTEN loss promotes resistance to EGFR presumably by dissociating EGFR inhibition from down-stream inhibition of the PI3K pathway 7, 14 . Inhibition of mTOR restores the sensitivity of PTEN-deficient gliomas to EGFR inhibitors 7, 15, 16 . Since 40% to 50% of glioblastomas lack PTEN expression, these findings were the rationale for the combined used of EGFR and mTOR inhibitors in human patients (see below). Furthermore, it became obvious that even in glioblastoma specimens with wild-6 type PTEN expression, resistance to EGFR inhibitors may occur as a result of phosphorylation of PTEN at the conserved tyrosine residue Y240 17 .
One of the most comprehensive strategies aiming at identifying molecules and pathways that mediate resistance to EGFR inhibition has been the use of genome-wide small hairpin (sh)RNA screens. The application of such an approach revealed the dopamine receptor D2
(DRD2) signalling pathway as a novel therapeutic target. Combined inhibition of DRD2 signalling and EGFR inhibition resulted in synergistic anti-glioma activity in in vitro and in vivo models 18 .
Glioma cells can be characterized by intrinsic resistance to EGFR inhibitors or acquired mechanisms that allow them to escape from EGFR-targeted treatment. Acquired resistance to EGFR inhibition in EGFR-mutant glioma cells is conferred by an induction of plateletderived growth factor receptor (PDGFR)-β expression. Consequently, the combined targeting of EGFR and PDGFR-β resulted in more potent anti-tumor activity in preclinical glioma models than either treatment alone 19 . Furthermore, expression of the promyelocytic leukemia The fact that not all tumor cells share the same molecular make-up may also contribute to resistance to EGFR inhibition. In this regard, a population of cells within gliomas that exhibit stem cell-like properties has been described within the last years. These cells, also known as glioma-initiating cells (GIC), have been proposed as a major factor for the ultimately lethal course of the disease due to their contribution to the resistance of gliomas to various treatments. Preclinical data indicate that the resistance of GIC to EGFR inhibition is partially due to focal adhesion kinase (FAK)-mediated integrin β1 signalling 21 . A similar study revealed that only co-treatment consisting of erlotinib and the hedgehog pathway inhibitor 7 cyclopamine had an effect on sphere initiation in glioblastoma stem-cell cultures 22 . These reports demonstrate that anti-EGFR strategies hold promise in targeting the stem cell population within glioblastomas. However, they also suggest that EGFR inhibition alone is insufficient and needs to be combined with the therapeutic targeting of at least one additional pathway. Further studies are required to define which combination may work best and which of the available combinations ultimately succeeds in human patients.
Clinical trials and combined treatment approaches in patients with malignant gliomas
Treatment 
Clinical administration of TKI
Several preclinical reports suggest a sensitizing effect of EGFR inhibition to irradiation 23 .
Accordingly, clinical trials were designed to explore the combination of radiation therapy with EGFR inhibitors in patients with newly diagnosed glioblastoma. However, such trials failed to show benefit from addition of gefitinib or erlotinib to radiation therapy compared to historical controls. Notably, these trials completed enrolment before the introduction of 8 temozolomide to the standard of care for glioblastoma patients 24, 25 27 . The combined administration of the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, and gefitinib did not achieve durable responses in patients with recurrent glioblastoma 28 . Similarly, a phase I/II trial exploring the combination of erlotinib with the mTOR inhibitor temsirolimus in patients with recurrent malignant glioma failed to prove relevant anti-tumor activity. However, doselimiting toxicity involving rash and mucositis was common 29 . Low tumor levels of both drugs and the failure to prove target inhibition in the posttreatment tissue of several patients may partially explain the futility of this regimen. Compared to the "first-generation" EGFR inhibitors, second-generation, irreversible, TKI may exert more potent anti-glioma activity.
However, one of these novel drugs, afatinib, did not show any signs of activity when used as single agent and did not improve the outcome of patients with recurrent glioblastoma in combination with temozolomide, likely because of negligible blood brain barrier penetration 30 . Other compounds such as dacomitinib (PF-00299804) are currently being tested in clinical trials enrolling patients with recurrent glioblastoma (NCT01520870 and NCT01112527).
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Anti-EGFR antibodies
The anti-EGFR antibody nimotuzumab was assessed in several clinical trials in patients with high-grade gliomas either alone or in combination with other treatment modalities and demonstrated only modest or no signs of activity 31, 32 . The lacking benefit of this regimen may be explained by the recent finding that treatment of glioma cells with an anti-EGFR antibody enhances DNA repair and thereby abrogates the effectiveness of DNA-damaging agents 33 . Accordingly, the development of more elaborated strategies that combine irradiation and/or alkylating chemotherapy with anti-EGFR strategies is required. 
Preclinical developments
Novel drug conjugates such as DAB389EGF, a fusion protein composed of diphtheria toxin linked to EGF have shown activity in experimental glioma models 38 . Further approaches that
have not yet reached the clinic include EGFR gene silencing by RNA interference or ribozyme-mediated cleavage of EGFR mRNA molecules 39, 40 . It needs to be awaited whether these techniques may become available for clinical testing in the future.
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Resistance to therapeutic approaches specifically targeting EGFRvIII
EGFRvIII has been described as a mediator of glioma cell resistance to chemotherapeutic drugs in vitro through up-regulation of the anti-apoptotic protein Bcl-XL 41 . However, the clinical impact of EGFRvIII expression on progression-free and overall survival has remained controversial. A report assessing tumor samples from 73 patients revealed an association of EGFRvIII expression with prolonged overall survival 42 . These authors also reported that EGFRvIII-negative neurosphere cells are more resistant to temozolomide than EGFRvIIIpositive cells suggesting that expression of EGFRvIII rather acts as a sensitizer to alkylating drugs. Notable, very high concentrations of TMZ were used for these in vitro studies which precludes translation into a clinical setting. Indeed, these findings are at odds with other reports. A study by Shinojima and colleagues revealed an association between EGFRvIII expression and poor overall survival in glioblastoma patients 43 . Ultimately, a comprehensive analysis of more than 180 glioblastoma patients demonstrated that the clinical course of EGFRvIII-expressing glioblastomas is not significantly different from that of patients harbouring EGFRvIII-negative tumors. However, long-term survival, defined by overall survival of more than 3 years, was virtually absent in patients with EGFRvIII-positive glioblastoma 44 .
Expression of EGFRvIII also defines a subgroup of tumor cells within a glioblastoma with stem cell characteristics 45 . It was reported that EGFRvIII is coexpressed with the putative stem cell marker CD133 and that these cells are characterized by the highest degree of selfrenewal as well as a pronounced tumorigenicity in vivo. On the cellular level, there is a close oncogenic signalling relationship between wild-type EGFR and EGFRvIII which drives glioblastoma progression 46 . Furthermore, a minority of cells within a glioblastoma expressing the EGFRvIII mutant may be sufficient to promote tumor growth by inducing the expression of several cytokines such as interleukin (IL)-6 and leukemia inhibitory factor (LIF).
Subsequently, these cytokines act in a paracrine manner on EGFRvIII-negative cells in the neighbourhood by accelerating their proliferation 47 . Accordingly, the specific targeting of EGFRvIII may have an impact on tumor growth beyond the population of EGFRvIII-positive cells. Proteomic analyses revealed that the expression of EGFRvIII results in the activation of different downstream pathways compared to gliomas that are EGFRvIII-deficient 48 . In this regard, preclinical data suggest a synergistic activity when EGFRvIII inhibition is combined with targeting of an additional pathway such as c-MET signalling or the urokinase-type plasminogen activator (uPAR) receptor pathway 49, 50 . It was also reported that resistance to anti-EGFR strategies is associated with increased expression of EGFRvIII and an activation of the PI3K pathway. The latter is accompanied by an induction of the expression of the regulatory 110-kDa delta subunit of PI3K (p110δ). Preclinical findings suggest that insulinlike growth factor receptor (IGFR)-I signaling via PI3K and the presence of major vault proteins (MVP) which stabilize EGFR/PI3K signalling also contribute to resistance to anti-EGFR therapy in glioma cells 51, 52 . Silencing of EGFRvIII resulted in a sensitization to the EGFR inhibitor erlotinib. Similary, targeting PI3K or the p110δ subunit also restored erlotinib sensitivity 53 . Considering these findings, the selective interfering with EGFRvIII signalling may help to overcome the treatment resistance of glioblastomas.
Immunotherapy: escape from vaccination against EGFRvIII
Since EGFRvIII is exclusively expressed on tumor cells, it represents an appealing target for therapeutic interventions. In contrast to wild-type EGFR which has been used as a point of attack for pharmacological inhibitors or antibodies, EGFRvIII has gained additional interest as target structure for active immunotherapy, that is, vaccination which aims at overcoming the immune evasion of glioma cells 54 
Outlook
TCGA has reconfirmed the EGFR gene as a principal target of mutation in glioblastoma, but also illustrated the variability of alterations. The history of negative trials with EGFR-targeted 13 agents teaches us that any future effort at exploiting this target for therapy must be based on a molecularly defined patient enrichment including at least EGFR status, but potentially also changes in associated pathways (Fig. 1) . Abbreviations: CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor;
EGFRvIII, EGFR variant III; mTOR, mechanistic target of rapamycin; PDGFR-β, plateletderived growth factor receptor β. ClinicalTrials.gov identifier: ACT IV (NCT01480479),
ReACT (NCT01498328)
